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Abstract. Background: Synthetic 6,7-annulated-4-
substituted indole compounds, which elicit interesting
antitumor effects in murine L1210 leukemia cells, were tested
for their ability to inhibit human HL-60 tumor cell
proliferation, disrupt mitosis and cytokinesis, and interfere
with tubulin and actin polymerization in vitro. Materials and
Methods: Various markers of metabolic activity, mitotic
disruption and cytokinesis were used to assess the
effectiveness of the drugs in the HL-60 tumor cell system.
The ability of annulated indoles to alter the polymerizations
of purified tubulin and actin were monitored in cell-free
assays and were compared to the effects of drugs known to
disrupt the dynamic structures of the mitotic spindle and
cleavage furrow. Results: With one exception, annulated
indoles inhibited the metabolic activity of HL-60 tumor cells
in the low-micromolar range after two and four days in
culture but these anti-proliferative effects were weaker than
those of jasplakinolide, a known actin binder that blocks
cytokinesis. After 24-48 h, antiproliferative concentrations of
annulated indoles increased the mitotic index of HL-60 cells
similarly to vincristine and stimulated the formation of many
bi-nucleated cells, multi-nucleated cells and micronuclei,
similarly to taxol and jasplakinolide, suggesting that these
antitumor compounds might increase mitotic abnormality,
induce chromosomal damage or missegregation, and block
cytokinesis. Since annulated indoles mimicked the effect of
vincristine on tubulin polymerization, but not that of taxol,
these compounds might represent a new class of microtubule
de-stabilizing agents that inhibit tubulin polymerization.
Moreover, annulated indoles remarkably increased the rate
and level of actin polymerization similarly to jasplakinolide,
suggesting that they might also stabilize the cleavage furrow
to block cytokinesis. Conclusion: Although novel derivatives
with different substitutions must be synthesized to elucidate
structure–activity relationships, identify more potent
antitumor compounds and investigate different molecular
targets, annulated indoles appear to interact with both
tubulin to reduce microtubule assembly and actin to block
cytokinesis, thereby inducing bi- and multinucleation,
resulting in genomic instability and apoptosis. 
Indole arynes, or indolynes, represent a new class of reactive
aryne intermediate (1-7) but the biological properties of
annulated indoles have not been fully-evaluated and
exploited. However, a few biologically-active natural products
such as trikentrins, herbindoles, teleocidins and nodulisporic
acids have been reported (8-11), suggesting that annulated
indoles may have unique structural features and a good
probability of exhibiting interesting biological activity (12).
Because annulated indoles have almost no representation in
the NIH PubChem and Molecular Library Small Molecule
Repository (MLSMR) databases, an unprecedented class of
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an indole-based library was constructed, using the indole
aryne methodology (12), and screened for antitumor activity
(13). Hence, 66 novel 6,7-annulated-4-substituted indole
compounds were synthesized, using a strategic combination
of 6,7-indolyne cycloaddition and cross-coupling reactions
under both Suzuki-Miyaura and Buchwald-Hartwig
conditions (12), and tested for their effectiveness against
murine L1210 tumor cell proliferation in vitro (13). Most
compounds inhibited the metabolic activity of L1210
lymphocytic leukemia cells in a time- and concentration-
dependent manner but only nine of them were sufficiently
potent to inhibit L1210 tumor cell proliferation by 50% in the
low micromolar range after two [concentration inhibiting by
50% (IC50)=4.5-20.4 μM] and four days [IC50=0.5-4.0 μM]
in culture (13). A 3-h treatment with antiproliferative
annulated indole was sufficient to inhibit, in a concentration-
dependent manner, the rate of DNA synthesis measured in
L1210 cells over a 0.5-h period of pulse-labeling with 3H-
thymidine (13). Four of the antiproliferative compounds had
weak DNA-binding activities but one compound reduced the
fluorescence of the ethidium bromide-DNA complex by up to
53%, suggesting that some annulated indoles might directly
interact with double-stranded DNA to disrupt its integrity and
prevent the dye from intercalating into DNA base pairs (13).
However, all nine antiproliferative compounds induced DNA
cleavage at 24 h in L1210 cells that contained 3H-thymidine-
prelabeled DNA, suggesting that these antitumor-annulated
indoles might trigger an apoptotic pathway of DNA
fragmentation (13). Indeed, these annulated indoles caused a
time-dependent increase of caspase-3 activity with a peak at
6 h (13). Interestingly, antiproliferative concentrations of
annulated indoles increased the mitotic index of L1210 cells
and stimulated the formation of many bi-nucleated cells
(BNCs), multi-nucleated cells (MNCs), apoptotic cells and
micronuclei (MNi) after 24-48 h, suggesting that these
antitumor compounds might increase mitotic abnormality,
induce chromosomal damage or missegregation, and block
cytokinesis to induce apoptosis (13). Therefore, the present
study was undertaken to determine the effectiveness of the six
most potent annulated indoles against human HL-60 tumor
cell proliferation, assess their ability to alter the kinetics of
tubulin and actin polymerization, and compare their effects to
those of drugs known to interact with microtubules (MTs) and
actin filaments in order to disrupt the functions of the mitotic
spindle and cleavage furrow.
Materials and Methods
Drug treatment, cell culture and proliferation assay. The synthesis
of 6,7-annulated-4-substituted indoles, using a strategic combination
of 6,7-indolyne cycloaddition and cross-coupling reactions under
both Suzuki-Miyaura and Buchwald-Hartwig conditions, may
represent the first example of library development that employs the
indole aryne methodology (12). The four steps of the synthesis
process, showing cycloaddition at the 6,7 position, followed by
cross-coupling at the C4 position have been summarized elsewhere
(13). Solutions of synthetic 6,7-annulated-4-substituted indoles,
known MT-disrupting anticancer drugs used as positive controls,
vincristine (VCR) and taxol (all from Sigma-Aldrich, St. Louis, MO,
USA), and the actin binder jasplakinolide (JAS; Calbiochem, EMD
Millipore, Billerica, MA, USA) were dissolved and serially diluted in
dimethyl sulfoxide (DMSO). Suspension cultures of human HL-60
promyelocytic leukemia cells (American Type Culture Collection,
Manassas, VA, USA) were incubated at 37˚C in a humidified
atmosphere containing 5% CO2 and maintained in continuous
exponential growth by twice-a-week passage in RPMI-1640 medium
supplemented with 10% fetal bovine calf serum (FCS; Atlanta
Biologicals, Norcross, GA, USA) and penicillin (100 IU/ml)-
streptomycin (100 μg/ml). HL-60 cell suspensions were grown in
triplicate in 48-well Costar cell culture plates for two and four days
in the presence or absence (control) of serial concentrations of
synthetic 6,7-annulated-4-substituted indoles to evaluate their
antiproliferative activity. Since compounds were supplemented to the
culture medium in 1-μl aliquots, the concentrations of vehicle in the
final incubation volume (0.5 ml) never exceeded 0.2% and did not
interfere with the data. Decreasing densities of cells, such as 125,000
and 37,500 HL-60 cells/0.5 ml/well, were initially plated in triplicate
at time 0 in order to collect control samples with approximately
equal cell densities after two and four days in culture, respectively.
The proliferation of control and drug-treated tumor cells was
assessed from their mitochondrial ability to bioreduce the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) reagent (Promega, Madison, WI,
USA) in the presence of phenazine methosulfate (PMS; Sigma) into
a water-soluble formazan product that absorbs at 490 nm (14). After
two or four days in culture, control and drug-treated HL-60 cell
samples were further incubated at 37˚C for 2.5 h in the dark in the
presence of 0.1 ml of MTS:PMS (2:0.1) and their relative metabolic
activity was estimated by recording the absorbance at 490 nm, using
a Cambridge model 750 automatic microplate reader (Packard,
Downers Grove, IL, USA) (13). Blank values for culture medium
supplemented with MTS:PMS reagent in the absence of cells were
subtracted from the results. Data of all biochemical experiments
were analyzed using Student’s t-test with the level of significance
set at p<0.05.
Mitotic index and abnormalities. To determine the mitotic index,
HL-60 cells (0.5×106/0.5 ml of FCS-containing RPMI-1640
medium) were incubated in triplicate for various periods of time at
37˚C in the presence or absence (control) of serial concentrations
of experimental drugs or known MT-disrupting and actin-stabilizing
agents, collected by centrifugation (200 g× 10 min), and re-
suspended in 1 ml of hypotonic 75 mM KCl for 20 min at 4˚C.
After fixation in 1 ml of MeOH:acetic acid (3:1), the final cell
pellets were collected by centrifugation, re-suspended in 75 μl of
MeOH:acetic acid (3:1), dispensed onto glass slides, air dried, and
stained by spreading 40 μl of 0.1% crystal violet under a coverslip
(13). Mitotic figures with condensed chromosomes were identified
microscopically and published criteria were followed to score
BNCs, MNCs and MNi (15). Cytokinesis-blocked BNCs contained
either two separate nuclei of equal size, two nuclei that touched or
overlapped with distinct nuclear boundaries, or two nuclei that were
linked by a small nucleoplasmic bridge (NPB) (15). Viable cells
with three (trinucleated) or four (quadrinucleated) distinct nuclei
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were scored as typical MNCs (15). Dot-like chromatin-containing
structures in the cytoplasm, at least one-third smaller than the main
nucleus, surrounded by a membrane either separated from or
marginally overlapping the main nucleus, and having the same
staining as the main nucleus were scored as MNi containing either
a whole chromosome or an acentric chromosomal fragment (15).
The frequencies of BNCs, MNCs and MNi were used to estimate
the ability of cytotoxic or genotoxic (mutagenic or clastogenic)
drugs to block cytokinesis and induce chromosomal damage or
missegregation (15). The percentage of cells in mitosis or with two
nuclei, MNCs and MNi were determined microscopically by
counting a total of at least 4,000 cells/slide and the mitotic, BNC
and MNC indexes were calculated as percentage of mitotic figures,
BNCs, or MNCs in drug-treated cultures relative to that in vehicle-
treated controls (13, 15).
Tubulin polymerization assay. The polymerization of purified tubulin
protein from bovine brain in the presence and absence of glycerol
was analyzed in a cell-free system using the Tubulin/Microtubule
Biochem Kit purchased from Cytoskeleton (Denver, CO, USA) (16-
18). The polymerization reactions contained, in a final volume of 0.2
ml, either tubulin without glycerol (1.15 mg/ml) or tubulin plus 15%
glycerol (2.25 mg/ml) in 80 mM PIPES buffer, pH 6.9, supplemented
with 10 mM MgCl2, 1 mM EGTA, 1 mM GTP and either 0 or 15%
glycerol. The annulated indoles and known MT-disrupting or actin-
stabilizing agents under study were all added to the assay mixture in
1-μl aliquots of DMSO to obtain the final concentrations tested. This
vehicle did not affect the kinetics of tubulin polymerization in drug-
untreated control reactions incubated in the presence or absence of
glycerol. The turbidity assay mixtures were immediately incubated
at 35˚C in quartz microcells and the rate and plateau of tubulin
polymerization were continuously monitored by scanning and
recording over 900 s the increased absorbance of the solution at 340
nm, using a Shimadzu UV-160 spectrophotometer (Shimadzu
Corporation, Kyoto, Japan) equipped with dual-beam optics and a
thermostatically-controlled cell holder (17, 18).
Actin polymerization assay. The purified actin protein from rabbit
skeletal muscle provided in the Actin Polymerization Biochem Kit
purchased from Cytoskeleton was used to analyze in a cell-free
system the polymerization of globular-actin (G-actin) monomers to
form long filamentous-actin (F-actin) with the concomitant
hydrolysis of ATP in the presence of divalent cations. There is a
critical concentration (CC) of free G-actin monomers below which
actin will not polymerize. At monomer concentrations above the CC,
actin will polymerize until the remaining free G-actin monomer
concentration becomes equal to the CC. The presence of Mg2+ and
KCl lowers the CC to induce nucleation and Mg2+ also stabilizes F-
actin. N-(1-Pyrenyl)iodoacetamide is a fluorophore that binds to the
thiol group of the Cys 374 residue of the G-actin monomers. Because
the very weak fluorescence of the pyrene-labeled G-actin is
dramatically enhanced upon incorporation into the double-helical
structure of F-actin filaments, the rate of actin polymerization in the
absence (control), and presence of annulated indoles and known
actin-stabilizing agent was monitored for 36 min at room
temperature by recording the increased fluorescence (365 nm
excitation and 407 nm emission) of pyrene-conjugated actin every
30 s-3 min (19, 20). The polymerization reactions contained, in a
final volume of 0.2 ml, 0.45 mg/ml of pyrene-labeled actin in 10 mM
Tris-HCl buffer, pH 7.5, supplemented with 0.2 mM CaCl2, 50 mM
KCl, 2 mM MgCl2, 5 mM guanidine carbonate and 1 mM ATP to
lower the CC and initiate the polymerization reaction, were placed
in 96-well Costar opaque assay plates and monitored, using a Cary
Eclipse Fluorescence Spectrophotometer equipped with a microplate
reader accessory (Varian, Walnut Creek, CA, USA). Data points were
the means of replicates from three different experiments and the
baseline fluorescence of pyrene-labeled G-actin in the absence of
polymerization-inducing buffer was subtracted from the results. 
Results
Inhibition of tumor cell proliferation. Six of the synthetic
6,7-annulated-4-substituted indole compounds reported to
have interesting antitumor effects in the L1210 tumor cell
system (13) were selected for the present study with human
HL-60 pro-myelocytic leukemia cells and their chemical
structures are shown in Figure 1. For simplification, the full
University of Kansas compound (KUC) identification
numbers of these compounds synthesized at the NIH Center
of Excellence in Chemical Methodologies and Library
Development at the University of Kansas (KU-CMLD) have
been logically abbreviated in our publications (13): for
example, KUC107070 is KU-70, KUC107072 is KU-72, et.
(Figure 1). All six compounds tested in the HL-60 tumor cell
system had anti-proliferative activities in the micromolar
range and their concentrations required to inhibit the
mitochondrial ability of HL-60 cells to metabolize the
MTS:PMS reagent by 50% after two and four days in culture
are indicated in Table I, except for KU-191 which did not
inhibit HL-60 cell proliferation by more than 34% and 48%
at days 2 and 4, respectively. These anti-proliferative IC50
values are always lower at day 4 than at day 2 because the
magnitude of inhibition between the control cells that keep
growing exponentially and the drug-treated cells that are
inhibited continues to widen over time (Table I). Full
concentration–response curves indicate that the time-
dependent inhibitions of HL-60 tumor cell growth by
antiproliferative KU-70, KU-72 and KU-80 at days 2 and 4
begin above 4 μM and become maximal or near-maximal
around 25-62.5 μM (Figure 2). However, when tested as
positive controls in the same experiments, established
anticancer drugs like daunorubicin and mitoxantrone (data
not shown), and JAS (Table I and Figure 2), a cell-permeable
F-actin probe with fungicidal, insecticidal and antitumor
properties, inhibited the growth of HL-60 tumor cells at
much lower nanomolar concentrations.
Mitotic index and abnormalities. Microscopic studies were
conducted to determine whether HL-60 tumor cells might
undergo mitotic disruptions after one and two days when
treated with 10-μM annulated indoles, which began to elicit
antiproliferative activities at day 2 (Figure 2). Control
populations of HL-60 tumor cells incubated in the absence of
drugs contained only 1.34% of mitotic cells and 2.66% of
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BNCs. Known MT-disrupting agents VCR and taxol were
used as positive controls in these experiments. VCR blocks
tubulin polymerization and MT assembly, whereas taxol
lowers the CC of free tubulin required to promote
polymerization and blocks MT disassembly. JAS, a potent
inducer of actin polymerization and stabilization, that
interferes with actomyosin ring function and impedes
cytokinesis (21-23), was also included for the sake of
comparison. Treatment with 0.05 μM VCR blocks cell-cycle
progression in the M-phase and dramatically increased the
percentage of mitotic cells by 9.8- and 3.7-fold at 24 and 48
h, respectively (Figure 3A). In contrast, 0.05 μM taxol and
0.32 μM JAS did not increase the mitotic index of HL-60
cells. Under similar conditions, 10 μM KU-70, KU-72 and
KU-80 mimic to a lesser degree the ability of VCR to block
mitosis, producing 1.5-, 4.8- and 2.6-fold increases,
respectively, in mitotic cells at 24 h (Figure 3A). This would
suggest some MT disruption but the effects of KU-70, KU-
72 and KU-80 declined or even disappeared at 48 h (Figure
3A). VCR and taxol increase BNCs by 2.6- and 5.7-fold,
respectively, at 24 h but not at 48 h (Figure 3B). Based on its
ability to stabilize the contractile actomyosin ring and block
the cleavage furrow, the actin binder JAS (21-23) induced a
9.5-fold increase in the percentage of BNCs at 
24 h that fully persists at 48 h (Figure 3B). Interestingly, KU-
70, KU-72 and KU-80 treatments also produced 5.2-, 4.9- and
4.6-fold increases, respectively, in the percentage of BNCs at
24 h, these stimulatory effects declined but remained
significant at 48 h (Figure 3B), indicating that the annulated
indoles rapidly induce molecular events that block the process
of cytokinesis in proliferating tumor cells. Control
populations of vehicle-treated HL-60 tumor cells contained
only 0.54% of MNCs and 0.04% of cells with MNi,
indicating that these abnormal figures of mitotic disruption
and genomic instability are extremely rare. The same VCR,
taxol, KU-70, KU-72, KU-80 and JAS treatments shown to
induce the development of BNCs also increased by 5.4-, 13.5-
, 10.6-, 9.6-, 9.7- and 4.1-fold, respectively, the percentage of
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Figure 1. Chemical structures and identification numbers of the synthetic 6,7-annulated-4-substituted indole compounds tested for their antitumor
effects in HL-60 cells in vitro.
MNCs at 24 h, with the effects of the annulated indoles
persisting at a reduced level at 48 h (Figure 4A). This is
consistent with the fact that drug-treated cells with disrupted
tubulin and actin dynamics and dysfunctional mitotic spindle
and cleavage furrow escape from mitosis without cytokinesis
and proceed as BNCs to the next cell cycle and round of
DNA synthesis to form MNCs and polyploid cells with 3-4
nuclei, which eventually die (15, 24). The VCR, taxol, KU-
70, KU-72, KU-80 and JAS treatments under study also
induced the development of 0.20, 0.44, 0.67, 0.57, 0.62 and
1.02%, respectively, of HL-60 cells with MNi at 24 h, with
the effects of the annulated indoles remaining almost
unaltered at 48 h (Figure 4B). These annulated indoles might,
therefore, enhance mitotic abnormalities, induce
chromosomal damage or missegregation, and block
cytokinesis. Finally, as compared to 15,000 control and VCR-
or taxol-treated HL-60 cells where no NPBs and nuclear buds
(NBUDs) were detected, 15,000 HL-60 cells treated with
KU-70, KU-72, KU-80 and JAS contained 3, 2, 6 and 2 NPBs
and 5, 13, 3 and 5 NBUDs, respectively, at 48 h (data not
shown). Control populations of HL-60 tumor cells incubated
for 48 h in the absence of drugs contained only 0.13% of cells
with five or more small nuclear structures, which is
microscopic evidence of nuclear fragmentation into smaller
apoptotic chromatin bodies within an intact cytoplasm and
cytoplasmic membrane (15). Using such criteria, VCR had no
effect but taxol, KU-70, KU-72, KU-80 and JAS treatments
increased the percentage of microscopically-visible apoptotic
tumor cells by 86.2-, 9.8-, 5.0-, 2.7- and 20.1-fold,
respectively (data not shown).
Inhibition of tubulin polymerization. The classic turbidity
assay was used to study the effects of anti-proliferative
annulated indoles on tubulin polymerization in the presence
or absence of glycerol. Normally, glycerol and taxol stabilize
tubulin and lower the CC of protein required to initiate MT
assembly (16). As shown by the control curve a concentration
of purified tubulin below 10 mg/ml cannot polymerize in the
absence of 15% glycerol (Figure 5A). However, the MT-
stabilizing drug taxol can easily induce the polymerization of
such a low concentration of tubulin (1.15 mg/ml) in the
absence of 15% glycerol (Figure 5A). In contrast to 10 μM
taxol, 300 μM KU-72 were not able to promote tubulin
polymerization in the absence of glycerol and, thus, is KU-
72 not a MT-stabilizing agent that blocks MT disassembly
like taxol (Figure 5A). The control curve in Figure 5B shows
the three typical phases of MT assembly taking place when
purified tubulin (2.25 mg/ml) undergoes polymerization in the
presence of 15% glycerol: a short lag phase, an exponential
growth phase almost linear between 100 and 400 s, and a
steady phase reaching a plateau after 520 s (16). At 10 μM,
compared to the control, VCR almost totally inhibited the rate
and extent of glycerol-induced tubulin polymerization by
94.5% and 93.7%, respectively (Figure 5B). At 300 μM, KU-
72 mimics the inhibitory effect of VCR and reduces the rate and
extent of glycerol-induced tubulin polymerization by 72.2% and
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Table I. Antiproliferative activity of synthetic 6,7-annulated-4-substituted
indole compounds in human HL-60 tumor cells in vitro. Concentrations
of novel synthetic indole-based compounds required to inhibit by 50%
(IC50) the metabolic activity of HL-60 leukemia cells, using the
MTS:PMS assay after two or four days of culture in vitro. The
antiproliferative activity of jasplakinolide (JAS) is indicated for the sake
of comparison. IC50 values (μM) were calculated from linear regression
of the slopes of the log-transformed concentration-survival curves. Data
are means±SD (n=3). NA: Values are not available because the
compound reduced tumor cell proliferation by less than 50% at the
highest concentration tested (156.25 μM).
Compounds IC50 values (μM) in HL-60 cells
Day 2 Day 4
KU-70 23.9±0.6 10.3±0.3
KU-72 33.8±0.8 12.7±0.6
KU-80 19.8±0.7 12.6±0.4
KU-96 33.1±1.2 21.5±0.6
KU-113 71.0±1.6 42.4±1.1
KU-191 NA NA
JAS 0.100±0.002 0.0177±0.0004
Figure 2. Comparison of the ability of serial concentrations (logarithmic
intervals) of KU-70, KU-72 and KU-80 to inhibit the metabolic activity of
HL-60 tumor cells at days 2 (open symbols) and 4 (solid symbols) in vitro.
The antiproliferative activities of jasplakinolide (JAS) concentrations at
days 2 and 4 are indicated for the sake of comparison. HL-60 cell
proliferation results are expressed as percentage of the net absorbance of
MTS/formazan after bioreduction by vehicle-treated control cells after two
(A490 nm=1.179±0.048) and four (A490 nm=1.149±0.047) days in culture
(100±4.1%, striped area). The blank values (A490 nm=0.370 at day 2 and
0.439 at day 4) for cell-free culture medium supplemented with MTS:PMS
reagent were subtracted from the results. Data are means±SD (n=3). aNot
different from respective controls; bp<0.05, cp<0.025 and dp<0.01,
significantly lower than respective controls.
70.5%, respectively, suggesting that this annulated indole, which
increased the mitotic cell index like VCR (Figure 3A), might
also be a MT de-stabilizing drug that prevents MT assembly
(Figure 5B). Glycerol-induced tubulin polymerization between
80 and 520 s is inhibited by 93.7% in the presence of 10 μM
of the known tubulin binder VCR but remains unaltered in the
presence of 5 μM of the known actin binder JAS (Figure 6).
In contrast, the three annulated indoles, which increased the
mitotic index of HL-60 tumor cells, are also capable of
inhibiting the polymerization of tubulin in the cell-free
turbidity assay. Indeed, 120 μM KU-70 and 300 μM KU-80
reduced the rate of glycerol-induced tubulin polymerization
by 57.9% and 59.0%, respectively, whereas 48, 120 and 300
μM KU-72 clearly induced concentration-dependent
inhibitory effects that reduced tubulin polymerization by 23.0,
46.3 and 70.5%, respectively (Figure 6).
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Figure 3. Comparison of the effects of KU-70 (10 μM), KU-72 (10 μM),
KU-80 (10 μM), vincristine (VCR, 0.05 μM), taxol (0.05 μM) and
jasplakinolide (JAS, 0.32 μM) on the frequency of mitotic figures (A)
and bi-nucleated cells (B) in HL-60 tumor cells in vitro. HL-60 cells
were incubated in triplicate for 24 (open columns) and 48 h (closed
columns) at 37˚C in the presence or absence (C: control) of the
indicated drugs. The percentage of cells in each category was
determined by morphological analysis, scoring an average of
approximately 5,000 cells/slide to identify those containing mitotic
figures or two nuclei. Results are expressed as the percentage of mitotic
(A) or bi-nucleated cells (B) in drug-treated cultures relative to the
mitotic (C: 1.34±0.12%) or binucleated (C: 2.66±0.23%) cells in
vehicle-treated controls. Data are means±SD (n=3). aNot different from
control; bp<0.005 and cp<0.0005, significantly smaller than respective
controls in A and B; dp<0.025, ep<0.005 and fp<0.0005, significantly
greater than respective controls in A and B.
Figure 4. Comparison of the effects of KU-70 (10 μM), KU-72 (10 μM),
KU-80 (10 μM), vincristine (VCR, 0.05 μM), taxol (0.05 μM) and
jasplakinolide (JAS, 0.32 μM) on the frequency of multi-nucleated cells
(A) and micronuclei (B) in HL-60 tumor cells in vitro. HL-60 cells were
incubated in triplicate for 24 (open columns) and 48 h (closed columns)
at 37˚C in the presence or absence (C: control) of the indicated drugs.
The percentage of cells in each category was determined by
morphological analysis, scoring an average of about 5,000 cells/slide
to identify those containing 3-4 nuclei or MNi. A: Results are expressed
as the percentage of multi-nucleated cells in drug-treated cultures
relative to the multi-nucleated cells (C: 0.54±0.04%) in vehicle-treated
controls. B: Results are expressed as the percentage of vehicle- (C:
0.04±0.002%) or drug-treated cells with MNi. Data are means±SD
(n=3). ap<0.0005, significantly smaller than control; bNot different from
respective controls in A and B; cp<0.025, and dp<0.0005, significantly
greater than respective controls in A and B.
Stimulation of actin polymerization. As indicated by the
control curve in Figure 7, the nucleation and polymerization
of purified G-actin (0.45 mg/ml) to form F-actin can be
induced by an actin-polymerizing buffer containing Mg2+ and
ATP and quantified by the fluorescence intensity of N-(1-
pyrenyl)iodoacetamide that increases as it becomes
incorporated into the double-helical structure of F-actin
filaments (19, 20). In relation to its ability to induce actin
nucleation, polymerization and stabilization (21-23), above
0.256 μM, JAS accelerates, in a concentration-dependent
manner, the rate at which the fluorescence of pyrene-labeled
actin develops to reach a plateau of maximal F-actin
polymerization (Figure 7). Interestingly, most of the
antiproliferative annulated indoles, except KU-96 which has a
marginal effect, appear to increase both the early rate and
maximal plateau of pyrene-labeled actin polymerization
(Figure 8) but the slower acceleration and greater magnitude
of these responses, compared with the control, suggests that
their interaction with actin might be slightly different from that
of JAS (Figure 7). Indeed, 250 μM KU-96, KU-191, KU-80,
KU-113, KU-72 and KU-70 respectively increased the rate of
actin polymerization by 1.2-, 1.5-, 1.6-, 1.6-, 1.8- and 2.0-fold
compared to control at 4 min. After all curves reach a plateau
at 19 min, these differences in the maximal levels of F-actin
formed persisted up to 30 min (Figure 8). Using the most
effective annulated indole shown in Figure 8, the
concentration-dependent ability of KU-70 to stimulate pyrene-
labeled actin polymerization in this fluorimetric assay is
demonstrated and substantiates the observation that annulated
indoles increase both the early rate and maximal level of F-
actin formation (Figure 9). KU-70 at 25, 62.5, 156.25 and
390.625 μM increased the rate of actin polymerization by 1.3-
, 1.4-, 1.7- and 3.1-fold, respectively, compared with the
control at 4 min and, when the curves reached a plateau at
about 9 min, these differences in the maximal level of F-actin
formed persisted up to 25 min (Figure 9).
Discussion
Since annulated indole structures are virtually unknown, it is
important to demonstrate that some members of the first
polycyclic annulated indole library constructed using a
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Figure 5. Comparison of the ability of antiproliferative KU-72 and known microtubule (MT)-stabilizing (A) and MT de-stabilizing (B) anticancer
drugs to respectively alter the kinetics of tubulin polymerization in the absence (A) or presence (B) of glycerol in vitro. A: Purified tubulin was
diluted to a final concentration of 1.15 mg/ml in 80 mM PIPES buffer, pH 6.9, containing 10 mM MgCl2, 1 mM EGTA and 1 mM GTP. The
polymerization reactions were placed in quartz microcells and incubated at 35˚C in the presence or absence (control) of 300 μM KU-72 or 10 μM
taxol. B: The turbidity assay mixtures were identical to those of (A) but contained 2.25 mg tubulin/ml and 15% glycerol. The polymerization reactions
were similarly incubated in the presence or absence (control) of 300 μM KU-72 or 10 μM vincristine (VCR). The rate of MT assembly was
continuously monitored by scanning over 900 s the increase in turbidity (absorbance at 340 nm). Assays were performed in duplicate.
tandem indole aryne cycloaddition/cross-coupling sequence
of reactions with the 4,6,7-tribromoindole platform (1-7, 12,
25) can induce antitumor effects in the micromolar range in
both the L1210 (13) and HL-60 cell systems. Interestingly,
the five annulated indoles that most inhibited HL-60 tumor
cell proliferation were from the Buchwald-Hartwig cross-
coupled products (i.e. those with an amine at the C-4
position of the indole), whereas the weaker antiproliferative
KU-191 compound came from the Suzuki-Miyaura series of
library members (13). The concentration-dependent
inhibition of HL-60 tumor cell proliferation by the annulated
indoles is always more pronounced at four rather than two
days, suggesting that the efficacy of these bioactive
compounds is a combination of their concentration and
duration of action. Because annulated indoles increasingly
block HL-60 cells in mitosis and slow down their
proliferation rate, the difference between the number of
exponentially growing untreated control cells and the number
of drug-treated cells continues to increase over time in
culture. KU-70, KU-72, KU-80, KU-96, KU-113 and KU-
191 were selected for the present HL-60 study because they
had the best anti-proliferative IC50 values in L1210 cells at
day 2 in relation with their ability to inhibit DNA synthesis
at 3 h and induce DNA fragmentation at 24 h. This suggests
that these annulated indoles are the most effective in short-
term antitumor assays and might have a more rapid
mechanism of action, needing less time to interact with and
be incorporated into cells, undergoing eventual metabolic
activation to reach crucial cellular targets, and trigger various
inhibitory pathways that finally damage and kill tumor cells
(13). The fact that the IC50 values of these compounds
required to inhibit the mitochondrial ability of tumor cells to
metabolize MTS:PMS reagent at day 4 are slightly higher in
HL-60 (10.3-42.4 μM) than L1210 cells (2.0-4.0 μM) (13)
might simply be due to the different rates of growth the cell
lines. Since suspension cultures of 105 viable L1210 and HL-
60 leukemia cells multiply 21- to 24-fold and 6- to 7-fold,
respectively, within seven days when fresh medium is
replenished, the anti-proliferative action of annulated indoles
might be more effective against unsynchronized populations
of rapidly-growing tumor cells that are frequently turning
through the cell cycle than against unsynchronized
populations of relatively slow-growing tumor cells that have
smaller growth fractions and divide less frequently.
Tubulin is a labile protein, unstable below 80 mM PIPES,
and should not be exposed to pH<6.8 or pH>7.0 and will not
polymerize in the presence of Ca2+ (16). The propensity of
tubulin subunits to assemble into MTs is dependent upon their
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Figure 7. Comparison of the abilitiy of serial concentrations of
jasplakinolide (JAS) to alter the kinetics of actin polymerization in vitro.
Assay mixtures (200 μl) containing pyrene G-actin (0.45 mg/ml) in 
10 mM Tris-HCl buffer, pH 7.5, with 0.2 mM CaCl2, 50 mM KCl, 2 mM
MgCl2, 5 mM guanidine carbonate and 1 mM ATP, were placed in 
96-well opaque assay plates and polymerization reactions were initiated at
room temperature in the absence or presence of JAS. The increasing
fluorescence of pyrene F-actin was monitored every 30 s to 3 min over a
36-min period at 365 nm excitation and 407 nm emission The baseline
fluorescence of pyrene-labeled G-actin (36.2±7.8 arbitrary units) in the
absence of polymerization-inducing buffer was subtracted from the results.
Data points are the means of replicates from three different experiments. 
Figure 6. Comparison of the ability of anti-proliferative KU-72, KU-80
and KU-70, jasplakinolide (JAS) and the known microtubule de-
stabilizing anticancer drug vincristine (VCR) to alter the kinetics of
glycerol-induced tubulin polymerization in vitro. The conditions of the
assays were identical to those of Figure 5B. The polymerization
reactions were incubated in the presence or absence (control) of 10 μM
VCR, 48, 120 or 300 μM KU-72, 300 μM KU-80, 120 μM KU-70, and
5 μM JAS. Results are expressed as the percentage of the rate of
glycerol-induced tubulin polymerization based on the linear increase in
turbidity between 80 and 520 s in vehicle-treated control assays (ΔA340
nm=0.190±0.012; 100±6.6%). Data are means±SD (n=2). aNot different
from control; bp<0.05, significantly less than control.
affinity for MT ends. In order to achieve MT assembly, this
affinity (the CC) has to be less than the total concentration of
free tubulin subunits (16). GTP and Mg2+ are necessary for
tubulin nativity, and glycerol stabilizes tubulin and lowers the
CC required to initiate polymerization (16). Taxol, which also
lowers the CC and eliminates the requirement for GTP,
promotes tubulin polymerization in the absence of glycerol and
stabilizes MTs by inhibiting their depolymerization (26, 27).
The effect of taxol on tubulin without glycerol and the effect
of glycerol on tubulin, therefore, can be used to screen for MT-
stabilizing and de-stabilizing drugs (26). A short lag phase is
necessary to create nucleation sites, which are small tubulin
oligomers from which larger MT polymers can form. Because
MT polymerization is readily reversible, a given population of
MTs is continually growing and shortening, a phenomenon
called dynamic instability (16). Thus, the growth phases
observed in Figure 5 reflect the rapid increase in the ratio of
MT assembly to disassembly. Finally, a steady phase is
established when the residual concentration of free tubulin
heterodimer equals the CC required to initiate polymerization
(16). The rate and extent of taxol-induced tubulin
polymerization may be faster and higher than those induced by
glycerol because taxol blocks MT disassembly. The kinetics of
taxol-, and glycerol-induced MT polymerization shown in
Figure 5 appear consistent with the initial concentrations of
1.15-2.25 mg tubulin/ml used in our reactions.
In contrast to the MT-stabilizing drug taxol (26, 27), a full
antiproliferative concentration of KU-72 cannot induce the
polymerization of tubulin without glycerol, suggesting that
this annulated indole neither promotes MT assembly nor
blocks tubulin de-polarization and MT disassembly.
However, KU-72 inhibits the rate and extent of
glycerol/Mg2+-induced polymerization of purified tubulin in
a concentration-dependent manner, demonstrating that this
annulated indole blocks MT assembly similarly to the known
MT de-stabilizing drugs that bind to tubulin on the
colchicine or vinblastine sites (26). KU-72 might inhibit
tubulin polymerization as a consequence of its binding
interaction with the α/β tubulin dimer, although other
mechanisms, such as interactions with Mg2+ ions or GTP, are
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Figure 8. Comparison of the ability of various anti-proliferative KU
compounds to alter the kinetics of actin polymerization in vitro. Assay
mixtures (200 μl) containing pyrene G-actin (0.45 mg/ml) in 10 mM Tris-
HCl buffer, pH 7.5, with 0.2 mM CaCl2, 50 mM KCl, 2 mM MgCl2, 5
mM guanidine carbonate and 1 mM ATP, were placed in 96-well opaque
assay plates and polymerization reactions were initiated at room
temperature in the absence (control) or presence of 250 μM KU-96, KU-
191, KU-80, KU-113, KU-72 and KU-70. The increasing fluorescence of
pyrene F-actin was monitored every 30 s to 3 min over a 36-min period
at 365 nm excitation and 407 nm emission The baseline fluorescence of
pyrene-labeled G-actin (38.5±8.6 arbitrary units) in the absence of
polymerization-inducing buffer was subtracted from the results. Data
points are the means of replicates from three different experiments.
Figure 9. Comparison of the ability of serial concentrations of anti-
proliferative KU-70 to alter the kinetics of actin polymerization in vitro.
Assay mixtures (200 μl) containing pyrene G-actin (0.45 mg/ml) in 10 mM
Tris-HCl buffer, pH 7.5, with 0.2 mM CaCl2, 50 mM KCl, 2 mM MgCl2, 5
mM guanidine carbonate and 1 mM ATP, were placed in 96-well opaque
assay plates and polymerization reactions were initiated at room
temperature in the absence or presence of KU-70. The increasing
fluorescence of pyrene F-actin was monitored every 30 s to 3 min over a
36-min period at 365 nm excitation and 407 nm emission The baseline
fluorescence of pyrene-labeled G-actin (40.2±9.4 arbitrary units) in the
absence of polymerization-inducing buffer was subtracted from the results.
Data points are the means of replicates from three different experiments.
conceivable (26). The Vinca alkaloid VCR is a spindle poison
which binds to tubulin, preventing MT assembly, causing
metaphase arrest and thus killing cells attempting mitosis
(26, 28). Although less strongly than VCR, annulated indoles
can inhibit the polymerization of purified tubulin in a cell-
free system but at concentrations much higher than those
shown to increase the mitotic index and inhibit the
proliferation of L1210 (13) and HL-60 cells. The fact that
the concentrations of anti-mitotic agents effective in the
tubulin polymerization assay are consistently higher than
those with cytostatic activity has been noticed before (17, 18,
26, 29). Anti-mitotic drugs interacting with a few essential
sites in the MTs might disrupt the mitotic spindle and be
cytostatic over a 2- to 4-day period at concentrations much
lower than those required to directly block the rate of
glycerol/Mg2+-induced tubulin polymerization in a cell-free
turbidity assay (17, 18, 26, 29). Indeed, mitotic arrest occurs
when less than 5% of the cellular tubulin is complexed by
colchicine (26). Nevertheless, the ability of annulated indoles
to inhibit tubulin polymerization and increase the mitotic
index suggests that these anti-tubulin and anti-mitotic effects
might play a role, at least in part, in the mechanism of their
anti-proliferative and anti-tumor activities.
Based on their ability to inhibit tubulin polymerization and
disrupt MT dynamics, KU-70, KU-72 and KU-80 would be
expected to arrest cells in the G2/M phase. The mitotic index
can differentiate between the anti-mitotic drugs that cause G2
or M phase arrest. Agents that arrest cells in the M phase,
such as VCR, increase the mitotic index but agents that cause
G2 arrest, such as etoposide (VP-16), reduce it. Since KU-
70, KU-72 and KU-80 increase the percentage of mitotic
figures and the mitotic index within 24 h, these annulated
indoles might be capable of causing metaphase arrest and
blocking the progression of HL-60 tumor cells in the M
phase of their cycle, although to a lesser degree than VCR.
When MT assembly is prevented in colchicine- or
nocodazole-treated cells, the level of unpolymerized tubulin
is increased and this, in turn, inhibits the formation of new
tubulin mRNA while the pre-existing message decays rapidly
(30). Since annulated indoles also inhibit DNA synthesis in
L1210 cells (13), the ability of these anti-proliferative
compounds to affect the level of translatable tubulin mRNA,
decrease tubulin production and alter other phases of the cell
cycle should be studied.
Anti-proliferative concentrations of annulated indoles
induce a time-dependent increase of caspase-3 activity,
which peaks at 6 h in L1210 cells and precedes the
fragmentation of radiolabeled DNA and the appearance of
apoptotic cells with five or more small nuclear structures at
24 h, suggesting that the ability of annulated indoles to
trigger apoptosis might play a significant role in their
molecular mechanism of antitumor activity (13). Even
though most of the anti-proliferative indoles, except KU-80,
do not directly bind to purified DNA to inhibit the
fluorescence of the ethidium bromide-DNA complex (13),
the abilities of these anti-tumor compounds to interact with
maintenance enzymes or regulatory proteins and indirectly
cause high molecular weight DNA-strand breaks, crosslinks
or chromosome aberrations and cytokinesis disruption should
be determined. Besides some tubulin interaction to disrupt
the polymerization of MTs, annulated indoles are likely to
target other molecular events in order to elicit their anti-
proliferative activity. For instance, anti-proliferative
concentrations of KU-69, KU-70, KU-72 and KU-80 might
trigger genotoxic effects that induce chromosomal
aberration, disrupt chromosomal segregation and block
cytokinesis to substantially increase the levels of BNCs,
MNCs and MNi in both L1210 (13) and HL-60 cells at 24-
48 h, the magnitudes of these responses often matching or
even surpassing those induced by VCR and taxol.
The presence of BNCs indicate that cytokinesis is
inhibited following nuclear division (15). MNCs may follow
if BNCs re-enter the cell cycle and escape further
cytokinesis. The MNi test is an indicator of drug-induced
chromosomal damage and aberration as such MNi structures
generally form during the metaphase/anaphase transition of
mitosis when a whole lagging chromosome or an acentric
chromosome fragment resulting from a clastogenic or
mutagenic event fail to integrate into the daughter nuclei
(15). However, chromosome aberration and non-
disjunction/missegregation might be the consequence of
prolonged drug-induced mitotic disruption and might be
responsible for the inability to undergo cytokinesis after
regression of the cleavage furrow (31). If completion of
cytokinesis requires accurate chromosome segregation,
annulated indoles might induce chromosome aberration and
missegregation to increase the frequency of BNCs, MNCs
and MNi in L1210 (13) and HL-60 cells. NPBs between
nuclei in BNCs originate from dicentric chromosomes in
which the centromeres have been pulled to the opposite poles
of the cell at anaphase and are indicative of DNA mis-repair,
chromosome re-arrangement or telomere end-fusions (15).
NPBs may break to form MNi. NPBs, which are correlated
with MNi frequency in BNCs, are thus biomarkers of
dicentric chromosomes and might provide indirect evidence
of annulated indole-induced genome damage resulting from
misrepaired DNA breaks. NBUDs occur during the S-phase
and form MNi that are still linked to the nucleus by a narrow
or wide stalk of nucleoplasmic material, depending on the
stage of the budding process. Amplified or excess DNA is
selectively localized to specific sites at the periphery of the
nucleus and is eliminated via nuclear budding to form MNi
during the S phase. Hence, annulated indoles and drugs that
inhibit DNA synthesis such as hydroxyurea might increase
the rate of elimination of amplified DNA and possibly DNA-
repair complexes via nuclear budding (32, 33).
ANTICANCER RESEARCH 34: 1643-1656 (2014)
1652
An interesting finding is that these annulated indoles mimic
the ability of JAS to stimulate the rate and level of F-actin
polymerization, an event which could stabilize the cleavage
furrow, inhibit cytokinesis and account for the formation of
many BNCs after KU-70, KU-72, KU-80 and JAS treatments.
Cytokinesis is a complex and multistep process of temporarily
and spatially coordinated action of the cell cycle and
cytoskeletal and membrane systems to achieve physical
separation of daughter cells by constriction of a cleavage furrow.
Because major cytokinesis proteins include components of the
cleavage furrow, such as actin, myosin and anillin, as well as
signaling systems that position and regulate the furrow, such as
aurora B and Polo kinases and Rho family GTPases, most
compounds currently known to inhibit cytokinesis are natural-
product actin binders and small-molecule inhibitors of aurora B
kinase. Both newly-polymerized and pre-existing F-actin
filaments can contribute to the initial assembly of the contractile
ring of actin and myosin that cleaves the cell into two. Once
formed, the ring remains a dynamic structure in which actin and
other ring components continuously assemble and disassemble
(34). Contractile ring formation requires highly regulated and
localized F-actin assembly, whereas its constriction depends
upon the action of myosin (35). Once the dense, bundled F-actin
network of the contractile ring is formed, myosin pulls on the
actin fibers to invaginate the plasma membrane. Soon after,
components of the contractile ring must be removed or
degraded to allow disassembly of the ring. JAS, a macrocyclic
peptide isolated from the sponge Jaspis johnstoni, competes
with phalloidin for actin binding and is a potent inducer of F-
actin nucleation, polymerization and stabilization (21, 22).
Because JAS is cell permeant, exhibits fungicidal, insecticidal
and anti-proliferative activities, and enhances apoptosis (36-39),
this peptide is useful in studying the role of actin dynamics in
cell processes such as adhesion, locomotion, endocytosis,
vesicle sorting and release, and cytokinesis. Our results are
consistent with the reports that an excessive accumulation and
delocalization of F-actin caused by JAS is linked to cytokinesis
failure, multinucleation, MNi and apoptosis (21-23).
Since actin dynamics are required to assemble and
disassemble the contractile actomyosin ring that cleaves the
mother cell into two daughter cells, actin binders, such as
JAS, that stimulate aberrant actin nucleation, polymerization,
stabilization and mislocalization might prevent constriction
of the cleavage furrow after nuclear division, block
cytokinesis and induce bi- and multi-nucleation, resulting to
genomic instability and apoptosis. Excessive polymerization
and stabilization of F-actin that interferes with the
functionality of the actomyosin ring during cytokinesis,
therefore, might also play a role in the mechanism by which
annulated indoles inhibit cytokinesis to cause multinucleation.
This hypothesis is substantiated by several studies
demonstrating that stabilized F-actin structures cause
massive cell division defects. For instance, cofilin, a
regulator of actin cytoskeletal dynamics essential for F-actin
turnover, is inhibited by phosphorylating kinases and
activated by dephosphorylating phosphatases, such as
chronofin. Hence, chronofin-expressing cells with active
cofilin can depolymerize F-actin to avoid excessive F-actin
accumulation, whereas chronofin-depleted cells with
increased levels of inactive phosphocofilin have aberrant
accumulation of F-actin, persistant contractile rings, and
cytokinesis failure, resulting in the formation of BNCs and
MNCs (40). Another example is that specific mutations of
the Wiskott-Aldrich syndrome protein (WASp) that
compromise normal auto-inhibition of WASp result in
unregulated activation of the actin-related protein 2/3
(ARP2/3) complex, which is essential for WASp-mediated
actin nucleation, and enhanced and delocalized F-actin
polymerization that cause defects of mitosis and cytokinesis
in X-linked neutropenia (23, 41). Transgenic expression of
mutant WASp caused hyperactivation and mislocalization of
F-actin polymerization, which led to the formation of BNCs,
MNCs and MNi, indicative of aborted cytokinesis and
genomic instability (23, 41). The increased and delocalized
F-actin induced by autoactive WASp during interphase
persists during all stages of mitosis, surrounding condensed
chromosomes and the mitotic spindle, and accumulating
around the spindle midzone during furrow ingression (23,
41). Conversely, prevention of excess F-actin production in
cells expressing mutant WASp reverses all the
antiproliferative and nuclear effects and also partially
restores normal mitotic timing (23, 42). The key features of
X-linked neutropenia, therefore, can all be traced to a
nonspecific mechanical disruption of cell division caused by
an excess of cytoplasmic F-actin polymerization (23, 41, 42).
Direct physical inhibition is speculated to explain how
excess F-actin, causing increased cellular viscosity, might slow
down all phases of mitosis, increase the frequency of lagging
chromosomes and block cytokinesis (23, 42). F-Actin
accumulation around the mitotic chromosomes might form a
physical barrier inhibiting chromosome capture and separation
by spindle MTs. A persistant F-actin network traversing the
cytoplasmic bridge left after actomyosin ring closure might
similarly impede cytokinesis by preventing abcission of the
daughter cells. Alternatively, excessive F-actin surrounding the
spindle midzone during late anaphase might inhibit the signal
from the spindle midzone to the cell cortex that is essential for
furrowing and cytokinesis (23, 42). Similarly, formins
contribute to the elongation of F-actin filaments to form the
dynamic contractile actomyosin ring but must be switched off
or degraded to allow disassembly of the contractile ring during
cytokinesis (43). Forced expression of activated formins,
therefore, is linked to hyperactivation and mislocalization of
F-actin polymerization, suggested to impede the intracellular
trafficking of membrane to the central spindle so crucial for
cleavage furrow invagination and subsequent separation (43).
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Overall, synthetic 6,7-annulated 4-substituted indoles might
be multi-functional anti-proliferative compounds advantageous
for disrupting both tubulin and actin dynamics, thereby
inducing mitotic abnormalities, cytokinesis failure, genomic
instability and apoptosis. Further structure–activity
relationships are required to identify more potent antitumor
lead compounds and characterize additional molecular targets
and mechanisms of action. 
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